

Are you prepared?



Cepheid Xpert[®] Tests: Your Complete Winter Care Bundle

Cepheid's Winter Care Bundle is a toolkit for the battle against infections, helping to reduce the potential for preventable ward closures, thereby averting a winter care crisis. Outbreaks of virulent infections — such as *Clostridium difficile*, norovirus, respiratory syncytial virus (RSV), influenza, and group A streptococcus — place a heavy clinical and financial burden on already strained healthcare resources. Molecular diagnostic testing with Cepheid's GeneXpert[®] System provides fast, accurate diagnosis, minimising the impact on hospital resources by enabling immediate implementation of infection control procedures and initiation of appropriate treatment. This helps to prevent the spread of disease and improve patient management, as well as support antibiotic and antiviral stewardships.



Xpert® Norovirus

Norovirus outbreaks in hospital environments have major cost implications,¹ making early diagnosis vital to ensure that affected individuals are isolated immediately and infection control measures are implemented. Cepheid's Xpert Norovirus is an on-demand, molecular diagnostic test offering increased sensitivity compared to EIA, quickly and efficiently identifying and differentiating between norovirus GI and GII in just 90 minutes. This fast, differential diagnosis can help healthcare providers deliver quicker treatment and as a result, reduce transmission and widespread outbreaks of the virus, as well as costly ward closures, decreasing the overall financial impact on the hospital.^{2,3}



Xpert[®] C. difficile BT

Clostridium difficile infections are reportedly the most common cause of hospital-acquired diarrhoea, and are associated with an increase in lengths and costs of hospital stays, as well as morbidity and mortality.⁴ Rapid accurate diagnosis of *C. difficile* is essential. Cepheid's Xpert *C. difficile* BT is the only rapid test to identify three targets: toxin B, binary toxin (BT), and *tcdC* deletion. It offers both speed and accuracy — detecting infections in just 47 minutes — with excellent sensitivity. This enables appropriate treatment and infection prevention and control measures to be initiated earlier, reducing the spread of infection and improving patient outcomes.⁵



Xpert[®] Xpress Flu/RSV

In any healthcare environment, fast, accurate diagnosis of influenza is vital for effective clinical management and infection control. Cepheid's Xpert Xpress Flu/RSV is a molecular diagnostic test capable of providing reliable, on-demand results in approximately 20° to 30 minutes, enabling real-time determination of Flu A, Flu B, and RSV infection and detection of the 2009 H1N1 strain, maximising clinical decision making.

 * For a positive result when running Flu or RSV alone



Xpert[®] Xpress Strep A

Pharyngitis caused by viruses or bacteria is one of the main reasons for visits to family physicians. Group A beta-hemolytic streptococcal is responsible for most of the bacterial infections and when left untreated might lead to a more serious condition.⁶ Since clinical findings alone do not adequately distinguish between viral or bacterial infections there is a need for a fast and reliable diagnostic test. Cepheid's Xpert **Xpress** Strep A is a molecular diagnostic test capable of providing reliable and timely results for effective therapy management.

References

1. Bartsch SM, et al. Global Economic Burden of Norovirus Gastroenteritis. PLoS ONE.2016. 11(4):e0151219.

EUROPEAN HEADQUARTERS

- 2. Mattner F, et al. Analysis of norovirus outbreaks reveals the need for timely and extended microbiological testing, Journal of Hospital Infection (2015), doi:10.1016/j.jhin.2015;08.020.
- 3. Cheng VC, et al. Prevention of nosocomial transmission of norovirus by strategic infection control measures. Infect Control Hosp Epidemiol. 2011;32:229-237.
- 4. Zilberberg MD, et al. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis. 2008 Jun;14(6):929-31.
- 5. National Prevalence Study of Clostridium Difficile in U.S. Healthcare Facilities. www.apic.org.
- 6. http://www.aafp.org/afp/2004/0315/p1465.html

IVD In Vitro Diagnostic Medical Device Not available in all countries. May not be available in the United States.

CORPORATE HEADQUARTERS

+1.408.541.4191

+1.408.541.4192

904 Caribbean Drive Sunnyvale, CA 94089 USA TOLL FREE +1.888.336.2743

PHONE

Vira Solelh 81470 Maurens-Scopont France PHONE +33.563.82.53.00 FAX +33.563.82.53.01

FAX +33.563.82.53.01 EMAIL cepheid@cepheideurope.fr

CEPHEID UK

www.Cepheidinternational.com

Wooburn Green, Buckinghamshire HP10 0HH UK PHONE +44 (0) 1628 564000

+44 (0) 1628 564000

EMAIL sales@cepheideurope.co.uk

Jupiter House, Mercury Park

3061-04